EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex)

Karmen Iessa, Kavita Kantilal iD, Ieda Garekyaragh, Lucy Paget, Yvonne Mangan, Yousif A Shamsaldeen iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Karmen Iessa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Applied Sciences, University of Brighton, Moulsecoomb, Brighton, East Sussex, UK. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is an aggressive type of skin cancer. Immune checkpoint inhibitors (ICIs): pembrolizumab, ipilimumab and/or nivolumab are recommended for the treatment of metastatic melanoma. ICIs enhance the immune response by blocking PD‐1 and/or CTLA‐4, improving remission and overall survival (OS). However, ICIs can cause immune‐related adverse events (irAEs) such as colitis and dermatitis. Recent studies have demonstrated association between irAEs and improved tumour regression. This study aimed to evaluate the relationship between OS and stopping ICIs therapy due to immunological toxicity in metastatic melanoma patients. This study was approved by The University Hospitals Sussex NHS Foundation Trust (UHSussex) (reference 1963) and the University of Brighton (reference 2024–12,878‐Shamsaldeen). Data collected from files of patients diagnosed with metastatic melanoma treated with ICIs at UHSussex between October 2011 to December 2022. In a total of 344 metastatic melanoma patients, the OS was 41.3%. There were 184 patients (53.5%) experienced irAEs. Among 202 patients who died by the cut‐off point, there were 115 (56.9%) patients who did not experience irAE, while 68.3% of the 142 patients who were alive experienced irAE revealing overall association ( p < 0.001, Pearson's R = 0.249) with logistics regression analysis showed association between irAE and OS ( p < 0.001). Kaplan–Meier survival analysis showed significant longer OS ( p < 0.001) for patients experienced irAE. Stopping ICIs due to toxicity reported in 83 patients from which 56 patients were alive by the cut‐off point (67.5%) revealing overall association ( p < 0.001, Pearson's R = 0.171) with logistics regression analysis showed association between stopping ICI due to toxicity and OS ( p < 0.001). Kaplan–Meier survival analysis showed significant longer OS ( p = 0.027) in patients whom their ICI therapy was stopped due to immune‐related toxicity. In conclusion, the positive correlation between irAEs and survival may highlight the potential value of irAEs and irAE‐related toxicity as biomarkers for therapeutic efficacy in advanced melanoma management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsSkin NeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansFemaleMaleMiddle AgedAgedIpilimumabAdultTreatment OutcomeHospitals, UniversityRetrospective StudiesAged, 80 and overAntibodies, Monoclonal, HumanizedTreatment Interruption

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune‐related adverse eventsimmunotherapymelanoma

Substanzen

Immune Checkpoint InhibitorsIpilimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pharmacy, School of Applied Sciences, University of Brighton, Moulsecoomb, Brighton, East Sussex, UK.
  • University Hospitals Sussex, Royal Sussex County Hospital, Brighton, East Sussex, UK.
  • Department of Pharmacy and Biomolecular Sciences, The Faculty of Health, Innovation, Technology and Science (HITS), Liverpool John Moores University, Liverpool, Merseyside, UK.

ORCID-Profile: Kavita Kantilal, Yousif A Shamsaldeen

Zitieren

APA

Iessa, K., Kantilal, K., Garekyaragh, I., Paget, L., Mangan, Y., & Shamsaldeen, Y. A. (2026). Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex). Cancer Medicine. https://doi.org/10.1002/cam4.72119

Vancouver

Iessa K, Kantilal K, Garekyaragh I, Paget L, Mangan Y, Shamsaldeen YA. Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex). Cancer Medicine. 2026. doi:10.1002/cam4.72119

BibTeX
@article{Iessa2026,
  author = {Iessa, Karmen and Kantilal, Kavita and Garekyaragh, Ieda and Paget, Lucy and Mangan, Yvonne and Shamsaldeen, Yousif A},
  title = {Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex)},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72119}
}
Kostenlos starten →